Innate Pharma (IPHA) EBT (2019 - 2025)
Innate Pharma's (IPHA) quarterly EBT came in at -$57.2 million in Q4 2025, down 8.28% YoY from -$62.4 million in Q4 2024, and down 136.93% on a QoQ basis from -$24.2 million in Q2 2025.
Innate Pharma (IPHA) EBT (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of EBT data on file, last reported at -$57.2 million in Q4 2025.
- Quarterly EBT fell 8.28% year-over-year to -$57.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$160.9 million (down 84.86% YoY) and the FY2025 annual result came in at -$57.2 million, down 8.28% from the prior year.
- EBT slipped to -$57.2 million in Q4 2025, from -$24.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of $618509.1 in Q2 2023 to a low of -$57.2 million in Q4 2025.
- A 5-year average of -$29.8 million and a median of -$26.7 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2021 — EBT sank 5435.2% — and 2022, when it soared 69.37%.
- Tracing IPHA's EBT over 5 years: stood at -$54.7 million in 2021, then soared by 69.37% to -$16.8 million in 2022, then jumped by 51.4% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then decreased by 8.28% to -$57.2 million in 2025.
- The last three EBT figures came in at -$57.2 million (Q4 2025), -$24.2 million (Q2 2025), and -$52.9 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Innate Pharma | 187.25 Mn | 187.25 Mn | - | -57.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | -24.16 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 618,509.05 |
| Dec 31, 2022 | -16.76 Mn |
| Dec 31, 2021 | -54.71 Mn |
| Jun 30, 2021 | -28.56 Mn |
| Dec 31, 2020 | -988,408.29 |
| Jun 30, 2020 | -11.38 Mn |
| Dec 31, 2019 | -22.98 Mn |